608 related articles for article (PubMed ID: 25833178)
21. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Schirmer SH; Baumhäkel M; Neuberger HR; Hohnloser SH; van Gelder IC; Lip GY; Böhm M
J Am Coll Cardiol; 2010 Dec; 56(25):2067-76. PubMed ID: 21144965
[TBL] [Abstract][Full Text] [Related]
22. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Vimalesvaran K; Dockrill SJ; Gorog DA
Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
[TBL] [Abstract][Full Text] [Related]
24. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
26. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.
Diener HC; Ntaios G; O'Donnell M; Easton JD
Expert Opin Pharmacother; 2018 Oct; 19(14):1597-1602. PubMed ID: 30152249
[TBL] [Abstract][Full Text] [Related]
27. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
28. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
29. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
30. Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
Gallù M; Marrone G; Legramante JM; De Lorenzo A; Di Daniele N; Noce A
Cardiovasc Ther; 2020; 2020():1743927. PubMed ID: 32684980
[TBL] [Abstract][Full Text] [Related]
31. The safety of edoxaban for treating atrial fibrillation.
Hammwöhner M; Goette A
Expert Opin Drug Saf; 2017 Nov; 16(11):1295-1303. PubMed ID: 28862063
[TBL] [Abstract][Full Text] [Related]
32. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
Shiyovich A; Khalameizer V; Katz A
Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
34. Non-vitamin K antagonist oral anticoagulants and heart failure.
Isnard R; Bauer F; Cohen-Solal A; Damy T; Donal E; Galinier M; Hagège A; Jourdain P; Leclercq C; Sabatier R; Trochu JN; Cohen A
Arch Cardiovasc Dis; 2016 Nov; 109(11):641-650. PubMed ID: 27836786
[TBL] [Abstract][Full Text] [Related]
35. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists.
Chen ST; Patel MR
Prog Cardiovasc Dis; 2018; 60(4-5):514-523. PubMed ID: 29339167
[TBL] [Abstract][Full Text] [Related]
37. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
38. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
Farag M; Gorog DA
Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
[TBL] [Abstract][Full Text] [Related]
40. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.
Kalabalik J; Rattinger GB; Sullivan J; Slugocki M; Carbone A; Rivkin A
Drugs; 2015 Jun; 75(9):979-98. PubMed ID: 25998374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
